Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Genitourinary Cancers: Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting

Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS
Released: September 1, 2020
Back Next

References

  1. Plimack ER, Rini BI, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5001.
  2. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116-1127.
  3. Tannir NM, McDermott DF, Escudier B, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 609.
  4. Atkins MB, Puzanov I, Plimack ER, et al. Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: long-term efficacy and safety from a phase Ib study. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5080.
  5. Choueiri TK, Kluger HM, George S, et al. FRACTION-RCC: innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5007.
  6. Atkins MB, Jegede O, Haas NB, et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5006.
  7. McKay RR, Xie W, McGregor BA, et al. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): a response-based phase II study (OMNIVORE). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5005.
  8. Callahan MK, Kania BE, Iyer G, et al. Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC). Program and abstracts of the 2017 American Society of Clinical Oncology Genitourinary Cancer Symposium. Abstract 384.
  9. Choueiri TK, Heng DYC, Lee JL, et al. SAVOIR: a phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5002.
  10. Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1-9.
  11. Albiges L, Heng DYC, Lee JL, et al. MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): pooled analysis of historical data. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract e19321.
  12. ClinicalTrials.gov. Testing cabozantinib, crizotinib, savolitinib and sunitinib in kidney cancer which has progressed. Available at: https://clinicaltrials.gov/ct2/show/NCT02761057. Accessed August 16, 2020.
  13. Gulati S, Philip E, Slagia S, et al. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun. 2020;23:100172.
  14. Powles T, Park SH, Voog E, et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract LBA1.
  15. Avelumab [package insert]. Rockland, MA: EMD Serono, Inc.; 2017.
  16. Grande E, Galsky MD, Arija JAA, et al. IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma. Program and abstracts of the 2019 European Society for Medical Oncology Congress. September 27 - October 1, 2019; Barcelona, Spain. Abstr LBA14_PR.
  17. Galsky MD, Pal SK, Mortazavi A, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. J Clin Oncol. 2019;37:15(suppl):4504.
  18. Rosenberg JE, Flaig TW, Friedlander TW, et al. Study EV-103: durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5044.
  19. Enfortumab vedotin-ejfv [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2019.
  20. Hoimes CJ, Rosenberg JE, Srinivas S, et al. EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Ann Oncol. 2019;30(suppl 5):v356-v402.
  21. Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37:2592-2600.
  22. ClinicalTrials.gov. Enfortumab vedotin and pembrolizumab, with or without chemotherapy, vs. chemotherapy alone in untreated locally advanced or metastatic urothelial cancer (EV-302). Available at: https://clinicaltrials.gov/ct2/show/NCT04223856. Accessed August 16, 2020.
  23. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50-54.
  24. Bauzon M, Drake PM, Barfield RM, et al. Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology. 2019;8:e1565859
  25. Hussain MHA, Powles T, Albers P, et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5000.
  26. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial [published correction appears in Lancet. 2018;392:1402]. Lancet. 2018;391:748-757.
  27. ClinicalTrials.gov. An investigational immuno-therapy study of nivolumab, compared to placebo, in patients with bladder or upper urinary tract cancer, following surgery to remove the cancer (CheckMate 274). Available at: https://clinicaltrials.gov/ct2/show/NCT02632409. Accessed August 16, 2020.
  28. ClinicalTrials.gov. Testing MK-3475 (pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer (AMBASSADOR). Available at: https://clinicaltrials.gov/ct2/show/NCT03244384. Accessed August 16, 2020.
  29. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-1026.
  30. Agarwal N, Loriot Y, McGregor BA, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results of cohort 6 of the COSMIC-021 study. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5564.
  31. Pal SK, Agarwal N, Loriot Y, et al. Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: results from cohort 2 of the COSMIC-021 study. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5013.
  32. Neal JW, Lim FL, Felip E, et al. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 9610.
  33. Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34:3005-3013.
  34. Sweeney CJ, Gillessen S, Rathkopf D, et al. IMbassador250: a phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract CT014.
  35. Bergerot P, Lamb P, Wang E, Pal SK. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18:2185-2193.
  36. Antonarakis ES, Pilots JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395-405.
  37. Tucker MD, Zhu J, Berry WR, et al. Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37:171-172.
  38. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246.
  39. Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30:1813-1820.
  40. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465-2474.
  41. Fizazi K, Shore ND, Tammela T, et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5514.
  42. Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197-2206.
  43. Jiang S, Terasawa E, Garcia Horton V, et al. Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5561.
  44. Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
  45. ClinicalTrials.gov. Androgen receptor directed therapy on cognitive function in patients treated with darolutamide or enzalutamide (ARACOG). Available at: https://clinicaltrials.gov/ct2/show/NCT04335682. Accessed August 16, 2020.
  46. Petrylak DP, Gao X, Vogelzang NJ, et al. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 3500.
  47. ClinicalTrials.gov. Clinical trial of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast Cancer (mBC). Available at: https://clinicaltrials.gov/ct2/show/NCT04072952. Accessed August 16, 2020.
  48. Hofman MS, Emmett L, Kaur Sandhu S, et al. TheraP: a randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603). Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 5500.
Back Next
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings